HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The complement system in systemic autoimmune disease.

Abstract
Complement is part of the innate immune system. Its major function is recognition and elimination of pathogens via direct killing and/or stimulation of phagocytosis. Activation of the complement system is, however, also involved in the pathogenesis of the systemic autoimmune diseases. Activation via the classical pathway has long been recognized in immune complex-mediated diseases such as cryoglobulinemic vasculitis and systemic lupus erythematosus (SLE). In SLE, the role of complement is somewhat paradoxical. It is involved in autoantibody-initiated tissue damage on the one hand, but, on the other hand, it appears to have protective features as hereditary deficiencies of classical pathway components are associated with an increased risk for SLE. There is increasing evidence that the alternative pathway of complement, even more than the classical pathway, is involved in many systemic autoimmune diseases. This is true for IgA-dominant Henoch Schönlein Purpura, in which additional activation of the lectin pathway contributes to more severe disease. In anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis the complement system was considered not to be involved since immunoglobulin deposition is generally absent in the lesions. However, recent studies, both in human and animal models, demonstrated complement activation via the alternative pathway as a major pathogenic mechanism. Insight into the role of the various pathways of complement in the systemic autoimmune diseases including the vasculitides opens up new ways of treatment by blocking effector pathways of complement. This has been demonstrated for monoclonal antibodies to C5 or C5a in experimental anti-phospholipid antibody syndrome and ANCA-associated vasculitis.
AuthorsMin Chen, Mohamed R Daha, Cees G M Kallenberg
JournalJournal of autoimmunity (J Autoimmun) Vol. 34 Issue 3 Pg. J276-86 (May 2010) ISSN: 1095-9157 [Electronic] England
PMID20005073 (Publication Type: Journal Article, Review)
CopyrightCopyright 2009 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Antineutrophil Cytoplasmic
  • Antibodies, Blocking
  • Complement System Proteins
Topics
  • Animals
  • Antibodies, Antineutrophil Cytoplasmic (immunology)
  • Antibodies, Blocking (therapeutic use)
  • Autoimmune Diseases (blood, genetics, immunology, therapy)
  • Complement Activation (genetics, immunology)
  • Complement System Proteins (genetics, immunology)
  • Cryoglobulinemia
  • Genetic Predisposition to Disease
  • Humans
  • Immune Complex Diseases (blood, genetics, immunology, therapy)
  • Immunotherapy
  • Systemic Vasculitis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: